Department of Clinical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
Cancer Treat Rev. 2012 Aug;38(5):505-14. doi: 10.1016/j.ctrv.2011.09.004. Epub 2011 Nov 17.
Epidermal growth factor receptor (EGFR) inhibitors, such as the monoclonal antibodies cetuximab and panitumumab, have proven efficacy in various types of cancer. However, these agents frequently result in skin toxicity, due to the expression of the EGFR in the skin. A correlation between the occurrence of skin toxicity and anti-tumor activity has been suggested in several phase III studies. However, since skin toxicity may impair the quality of life, and severe skin toxicity requires dose reduction or interruption, adequate and timely management of skin toxicity is important to maximize the anti-tumor efficacy of the EGFR inhibitor, as well as maintaining the patient's quality of life. Due to the small number of randomized controlled trials conducted in the field of EGFR inhibitor-induced skin toxicity so far, it is not possible yet to generate evidence based guidelines on its management. Here, we review and discuss available trials and case studies reporting on the management of EGFR inhibitor-induced skin toxicity.
表皮生长因子受体（EGFR）抑制剂，如单克隆抗体西妥昔单抗和帕尼单抗，已被证明在多种癌症中具有疗效。然而，由于 EGFR 在皮肤中的表达，这些药物经常导致皮肤毒性。在几项 III 期研究中已经提出了皮肤毒性的发生与抗肿瘤活性之间的相关性。然而，由于皮肤毒性可能会损害生活质量，并且严重的皮肤毒性需要减少剂量或中断治疗，因此充分和及时地管理皮肤毒性对于最大限度地提高 EGFR 抑制剂的抗肿瘤疗效以及维持患者的生活质量非常重要。由于迄今为止在 EGFR 抑制剂引起的皮肤毒性领域进行的随机对照试验数量较少，因此目前还无法制定关于其管理的基于证据的指南。在这里，我们回顾和讨论了现有的试验和病例研究报告，这些报告涉及 EGFR 抑制剂引起的皮肤毒性的管理。
